Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

GlaxoSmithKline has asked the US regulator to expand the licence of its injected lung drug mepolizumab, to include chronic obstructive pulmonary disease (COPD). Under the brand name Nucala ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

There are currently five biologics approved to treat asthma, according to the American Academy of Allergy, Asthma, and Immunology: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.

GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES). It’s part of the company’s focus on ...

Three biologics have come onto the market since 2019: Nucala (mepolizumab) , Dupixent (dupilumab) , and Xolair (omalizumab) . “Although these drugs can be expensive, they are a good option to ...

The CHMP’s recommendation is based on results from the MANDARA phase 3 trial, which compared efficacy and safety of benralizumab vs mepolizumab, the only approved treatment for EGPA, in patients ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

November 12, 2024 • One in four U.S. households experiences a power outage each year. Scientists at Oak Ridge National Laboratory are working on technology they hope will help fix electric grids ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...